{"id":"W4401539643","doi":"10.1016/j.lungcan.2024.107928","title":"Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma","year":2024,"lang":"id","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Sanofi Genzyme; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Jazz Pharmaceuticals; European School of Oncology; AstraZeneca; Novocure; Invitae; Silverback Therapeutics; Verily Life Sciences; Boston Pharmaceuticals; Takeda Oncology; Mirati Therapeutics; Chugai Pharmaceutical; Lung Cancer Research Foundation; Revolution Medicines; International Association for the Study of Lung Cancer; U.S. Department of Defense; Sanofi; Bristol-Myers Squibb; Pfizer; University of Miami; National Cancer Institute; Bayer; Mesothelioma Applied Research Foundation","keywords":"Pembrolizumab; Medicine; Randomized controlled trial; Mesothelioma; Internal medicine; Oncology; Pathology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002311806,0.002265299,0.00463311,0.0004714242,0.0005881464,0.001845394,0.00171164,0.002173261,0.01177641],"category_scores_gemma":[0.003023547,0.001267323,0.003783119,0.0004179821,0.001727529,0.001972291,0.0007576015,0.005666734,0.001688647],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00161158,"about_ca_system_score_gemma":0.001275766,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002133195,"about_ca_topic_score_gemma":0.003222976,"domain_scores_codex":[0.9985715,0.000754047,0.000100353,0.0002888765,0.00007745114,0.0002077331],"domain_scores_gemma":[0.9983444,0.0006139741,0.0003607383,0.0001678725,0.0001002203,0.0004128223],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9951403,0.0007958415,0.0001139751,0.0001778106,0.0008539545,0.00001343358,0.00001043476,0.000151069,0.0005075858,0.00006114006,0.0001715213,0.002002874],"study_design_scores_gemma":[0.9736075,0.02348165,0.0007327975,0.00002797741,0.001072009,0.00001634704,0.0000168711,0.0003657612,0.0001438039,0.0001686284,0.0003538029,0.00001281037],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9806279,0.006615697,0.0009059922,0.001556438,0.002864781,0.00236538,0.001413455,0.0001338982,0.003516436],"genre_scores_gemma":[0.9885689,0.001693071,0.00110963,0.0009914715,0.0007384571,0.001678152,0.0009217427,0.00002926518,0.004269426],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01177641,"threshold_uncertainty_score":0.03939605,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01490438308467137,"score_gpt":0.3307358708547637,"score_spread":0.3158314877700923,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}